PMID- 11699400
OWN - NLM
STAT- MEDLINE
DCOM- 20020116
LR  - 20190116
IS  - 1042-8194 (Print)
IS  - 1026-8022 (Linking)
VI  - 42
IP  - 3
DP  - 2001 Jul
TI  - Treatment of post-transplanted, relapsed patients with hematological malignancies 
      by infusion of HLA-matched, allogeneic-dendritic cells (DCs) pulsed with 
      irradiated tumor cells and primed T cells.
PG  - 357-69
AB  - Patients with hematological malignancies who relapse after bone marrow 
      transplantation (BMT) are often treated with donor lymphocyte infusion. However, 
      this procedure often results in graft-versus-host disease (GVHD). While, 
      Dendritic cells (DCs), which present antigens to naive T cells, have been used in 
      the immunotherapy of cancer, this approach has been logistically difficult due to 
      limiting numbers of DCs. We have now developed a method for obtaining a large 
      number of DCs by treating the granulocyte colony-stimulating factor (G-CSF) 
      mobilized peripheral blood stem cells (PBSCs) from healthy donors with 
      granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-4 (IL-4), 
      and tumor necrosis factor-alpha (TNF-alpha). The resulting cells possess the 
      morphologic, phenotypic, and functional characteristics of mature DCs. In in 
      vitro studies, culture of these HLA-matched donor derived-DCs with irradiated 
      each patient's tumor cells as an antigen source, followed by incubation with T 
      cells from the patient, induced the production of highly cytotoxic T lymphocytes 
      (CTLs) specific for the respective tumor cells in the semi-allogeneic setting. A 
      transient, but objective clinical response was obtained in the absence of GVHD 
      when we injected the DCs which had been pulsed with irradiated tumor cells as 
      well as primed T cells from the same original donor of related- allogeneic stem 
      cell transplantation into the relapsed patients. Our findings suggest that 
      treatment of relapsed patients with such donor-derived DCs, and primed T cells 
      may be effective as an adjunctive immunotherapy.
FAU - Fujii, S
AU  - Fujii S
AD  - Centre for Bone Marrow Transplantation and Immunotherapy, Institute for Clinical 
      Research, Kumamoto National Hospital, 1-5 Ninomaru, Kumamoto 860-0008, Japan. 
      fujii1018@aol.com
FAU - Shimizu, K
AU  - Shimizu K
FAU - Fujimoto, K
AU  - Fujimoto K
FAU - Kiyokawa, T
AU  - Kiyokawa T
FAU - Tsukamoto, A
AU  - Tsukamoto A
FAU - Sanada, I
AU  - Sanada I
FAU - Kawano, F
AU  - Kawano F
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Leuk Lymphoma
JT  - Leukemia & lymphoma
JID - 9007422
RN  - 0 (Antigens, CD)
RN  - 0 (Interleukin-2)
RN  - 83869-56-1 (Granulocyte-Macrophage Colony-Stimulating Factor)
SB  - IM
MH  - Adult
MH  - Antigens, CD/analysis
MH  - Cytotoxicity, Immunologic
MH  - Dendritic Cells/immunology/*transplantation
MH  - Female
MH  - Graft vs Host Disease/prevention & control
MH  - Granulocyte-Macrophage Colony-Stimulating Factor/therapeutic use
MH  - Hematologic Neoplasms/immunology/*therapy
MH  - *Hematopoietic Stem Cell Transplantation
MH  - Histocompatibility Testing
MH  - Humans
MH  - Hypersensitivity, Delayed
MH  - Immunophenotyping
MH  - Interleukin-2/therapeutic use
MH  - Lymphocyte Culture Test, Mixed
MH  - Lymphocyte Subsets/immunology
MH  - Lymphocyte Transfusion
MH  - Male
MH  - Middle Aged
MH  - Recurrence
MH  - Skin Tests
MH  - T-Lymphocytes/immunology/*transplantation
MH  - Transplantation, Homologous
EDAT- 2001/11/09 10:00
MHDA- 2002/01/17 10:01
CRDT- 2001/11/09 10:00
PHST- 2001/11/09 10:00 [pubmed]
PHST- 2002/01/17 10:01 [medline]
PHST- 2001/11/09 10:00 [entrez]
AID - 10.3109/10428190109064592 [doi]
PST - ppublish
SO  - Leuk Lymphoma. 2001 Jul;42(3):357-69. doi: 10.3109/10428190109064592.